Protalix Ltd.
25Patents
24Active
25Granted
50Portfolio score
Filing activity: Oct 11, 2005 → Apr 8, 2022 · 7 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7655781B2 | Variants of human glycoprotein hormone alpha chain: compositions and uses thereof | Human Necessities | 18 | Active |
| US7951557B2 | Human lysosomal proteins from plant cell culture | Chemistry; Metallurgy | 17 | Active |
| US8741620B2 | Human lysosomal proteins from plant cell culture | Chemistry; Metallurgy | 13 | Active |
| US8449876B2 | Human lysosomal proteins from plant cell culture | Chemistry; Metallurgy | 10 | Active |
| US8790641B2 | Production of high mannose proteins in plant culture and therapeutic uses thereof | Chemistry; Metallurgy | 9 | Active |
| US8227230B2 | Human lysosomal proteins from plant cell culture | Chemistry; Metallurgy | 9 | Active |
| US9194011B2 | Stabilized alpha-galactosidase and uses thereof | Human Necessities | 6 | Active |
| US10364413B2 | Large scale disposable bioreactor | Chemistry; Metallurgy | 4 | Active |
| US9708595B2 | Stabilized alpha-galactosidase and uses thereof | Human Necessities | 3 | Active |
| US8119406B2 | System and method for production of antibodies in plant cell culture | Chemistry; Metallurgy | 2 | Expired |
| US10280414B2 | Stabilized α-galactosidase and uses thereof | Human Necessities | 2 | Active |
| US10000551B2 | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Chemistry; Metallurgy | 2 | Active |
| US10087232B2 | Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy | Emerging Cross-Sectional Technologies | 1 | Active |
| US11225648B2 | Modified DNase and uses thereof | Human Necessities | 1 | Active |
| US10870842B2 | Stabilized alpha-galactosidase and uses thereof | Human Necessities | 1 | Active |
| US12194079B2 | Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase | Chemistry; Metallurgy | 0 | Active |
| US9603907B2 | Dry powder formulations of dNase I | Chemistry; Metallurgy | 0 | Active |
| US10730925B2 | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Emerging Cross-Sectional Technologies | 0 | Active |
| US9732333B2 | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells | Chemistry; Metallurgy | 0 | Active |
| US9220737B2 | Plant cell culture expressing human lysosomal proteins and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12385054B2 | Removal of constructs from transformed cells | Chemistry; Metallurgy | 0 | Active |
| US12385026B2 | Stabilized alpha-galactosidase and uses thereof | Human Necessities | 0 | Active |
| US11814657B2 | Modified DNase and uses thereof | Human Necessities | 0 | Active |
| US8742079B2 | Saccharide-containing protein conjugates and uses thereof | Human Necessities | 0 | Active |
| US9603906B2 | Inhalable liquid formulations of DNase I | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.